Alleviant Medical
Alleviant Medical, Inc. is a clinical-stage medical device company headquartered in Austin, Texas, founded in 2017 to develop minimally invasive, transcatheter therapies for heart failure. The Alleviant System is an investigational, no-implant approach that creates a small interatrial passageway to relieve elevated left atrial pressure without leaving a permanent device behind; it holds U.S. FDA Breakthrough Device designation for both preserved and reduced ejection fraction heart failure and is under study in the FDA-approved ALLAY-HF and ALLAY-HFrEF pivotal trials. The company has raised roughly $164M across a $75M round led by S3 Ventures and RiverVest Venture Partners and a $90M round led by Gilde Healthcare with Omega Funds, Vensana Capital, Longview Ventures, Gilmartin Capital and the TMC Venture Fund. Alleviant is a device and clinical-trial business, not a software business: it publishes no developer portal, no public API, no SDK and no machine-readable specification, and its public web surface is limited to clinician, patient-education, investor and press material.
Alleviant Medical is profiled on the APIs.io network. Tagged areas include Company, Medical Devices, Health Care, Cardiology, and Heart Failure.
Alleviant Medical’s developer surface includes engineering blog and 15 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Get Started 1
Portal, sign-up, and the first successful call
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 5
The organization behind the API
Other 5
Properties that don't map to a standard resource type